Advanced Therapies 2021 | Autologous vs allogeneic therapy: how will this space evolve?
Sven Kili, MD, Antion Biosciences SA, Geneva, Switzerland, provides an overview of the current landscape of autologous and allogeneic cell therapies. Whilst autologous approaches hold potential in delivering personalized therapies for small patient cohorts and rare diseases, allogeneic therapies are expected to become increasingly used in more common indications with larger patient cohorts. Nevertheless, there are still a number of remaining scientific challenges that need to be addressed in order to make large-scale allogeneic approaches a reality, including issues around cell expansion, banking and release criteria. This interview took place at the Advanced Therapies Congress & Expo 2021.
Disclosures
Sven Kili has the following disclosures:
Antion Biosciences – CEO;
Sven Kili Consulting – Principal;
CCRM – Board Member;
UK Innovation Hubs – Steering Committee Chair;
LGC Corporation – SAB Member;
ISCT – BM&I Committee Chair & 2022 Annual Meeting co-chair;
BIA – CGTAC Chair;
Xintela AB – Board Member;
UCL MSc in Manufacturing & Commercialisation of Cell & Gene Therapes – Steering Committee chair
